Traveler’s Diarrhea Treatment Market (Drug Class: Oral Rehydration Therapy (ORS), Antidiarrheal Agents, Antibiotics [Azithromycin, Ciprofloxacin, Quinolones, and Rifaximi], Vaccines/Prophylactics, and Others; Pathogen: Bacteria [E. Coli, Salmonella Spp, and Others], Viruses, and Protozoa; Age Group: Adults and Children; and Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2030

Travelers Seek Solutions to Counter Diarrheal Pathogens in Tropical Regions

International travel has gained significant momentum in the past decade and the trend is showing no signs of slowing down. As per the data released by the World Tourism Organization (UNWTO), an astounding 1.4 billion international tourist arrivals were recorded - a 6% rise from 2017. As per the observable trends, tourists are traveling in huge numbers to tropical and sub-tropical countries, including Thailand, Spain, and India. However, tourists are at a high risk of being exposed to diarrheal pathogens in these regions and thus, traveler’s diarrhea has emerged as one of the most common health problems faced by international travelers.

Traditionally, antibiotic prophylaxis is used to prevent traveler’s diarrhea, which is primarily caused by bacterial etiologies. The traveler’s diarrhea treatment market is expanding at a rapid pace, as awareness among travelers related to ill effects of traveler’s diarrhea is increasing. Furthermore, drug approvals by the FDA, rise in the number of research activities, and development of new therapeutics are some of the leading factors that are expected to drive the traveler’s diarrhea treatment market. The market for traveler’s diarrhea treatment is expected to reach a value of ~US$ 1.3 Bn by 2027.

FDA Approvals for New Drugs for Treatment of Traveler’s Diarrhea

Antibiotics used to treat and manage traveler’s diarrhea have evolved at a rapid pace in the past 50 years due to a range of factors, including drug resistance, costs, and side-effects. However, with consistent developments in research, new and improved treatments for traveler’s diarrhea are entering the traveler’s diarrhea treatment market.

The Food and Drug Administration (FDA) has given approval to several new treatments and drugs in recent years. For instance, Aemcolo, an oral antibacterial rifamycin, was approved by the FDA in November 2018 to treat traveler’s diarrhea caused by E.coli. Clinical studies have revealed that rifamycin has greater efficiency in reducing the symptoms of diarrhea symptoms compared to placebo. Antibiotics are primarily recommended to treat severe traveler’s diarrhea. Despite a few side effects, within the drug class segment, antibiotics are likely to stay ahead with a market share of ~51% during the forecast period. The management and treatment of traveler’s diarrhea are expected to evolve, owing to the formulation of different guidelines laid down by regulatory bodies worldwide. As per the new guidelines, the use of antibiotics for mild traveler’s diarrhea is not recommended, as they have been linked to adverse events.

Antidiarrheal agents, such as bismuth subsalicylate and loperamide, are predominantly used in conjunction with antibiotics to offer instant relief from the symptoms of traveler’s diarrhea. The treatment of traveler’s diarrhea primarily depends on the severity of the treatment. Oral rehydration solutions are ideally used to treat traveler’s diarrhea in children, infants, and geriatric population, as these patients are more susceptible to dehydration and electrolyte imbalance. The oral rehydration solution and antidiarrheal segments of the traveler’s diarrhea treatment market are collectively expected to reach a value of ~US$ 511 Mn by the end of 2027.

Bacteria to Retain Lead as Primary Traveler’s Diarrhea-causing Pathogen

Traveler’s diarrhea is predominantly caused by pathogens such as viruses, bacteria, and protozoa. Of these, nearly 80% of the cases are caused by bacteria, and thus, this segment is projected to account for ~ 69% share of the traveler’s diarrhea treatment market in 2019. Viruses are the causative agents for ~5-10% cases depending on geographical location. As per the Centers for Disease Control and Prevention data, norovirus and rotavirus are the leading types of viruses that cause traveler’s diarrhea. E.coli and Salmonella Spp are the two major bacteria types responsible for traveler’s diarrhea. According to the British Medical Journal, the prevalence of traveler’s diarrhea is higher among travelers visiting regions in South Asia and Southeast Asia. Thus, the traveler’s diarrhea treatment market is expected to grow during the forecast period.

Analysts’  Viewpoint

The traveler’s diarrhea treatment market is expected to expand at a healthy CAGR of ~7% during the forecast period. Development of new drugs, growing awareness among travelers, and approval from the FDA will continue to play an imperative role in the growth of the traveler’s diarrhea treatment market in the near future. Companies in the traveler’s diarrhea treatment market landscape should focus on the development of new drugs and ensure they are compliant with the current guidelines. Among regions, with a market share of ~42% in 2018, North America will retain its lead during the forecast period, owing to product approvals and early adoption of new products. 

Traveler’s Diarrhea Treatment Market: Overview

The traveler’s diarrhea treatment market for the historical period of 2017 - 2018 and forecast period of 2019 - 2027, a surge in the number of travelers and rise in awareness among travelers about traveler’s diarrhea is anticipated to drive the traveler’s diarrhea treatment market

According to the report, the global traveler’s diarrhea treatment market was valued at ~US$ 738 Mn in 2018. It is projected to expand at a CAGR of ~7% from 2019 to 2027

Surge in Number of Travelers and Awareness Among Travelers: A Key Driver

The risk of acquiring traveler’s diarrhea is high in developing countries such as those in Africa, the Middle East, Asia, and Latin America. Increase in number of travelers to developing countries in these regions is driving the number of traveler’s diarrhea patients.

For instance, according to The World Tourism Organization (UNWTO), in 2018, estimated international tourist arrivals (overnight visitors) increased 6% to 1.4 billion across the world

According to the worldatlas, Southeast Asia receives the highest number of travelers and an estimated 55.6 million people visited China, Thailand received 24.8 million visitors, South Korea welcomed 14.2 million, Japan 13.4 million, and Indonesia received 10.4 million visitors annually

As per the Center for Disease Control and Prevention (CDC), in 2016, more than 6 million international travelers visited Brazil

Rise in number of travelers is boosting travel expenditure. For instance, according to The U.S. Travel Association, in the U.S., an estimated US$ 1.1 trillion was spent by domestic and international inbound travelers.

Rise in awareness among travelers is anticipated to drive the global traveler’s diarrhea treatment market. For instance, pre-travel counseling is essential, due to a rise in number of travelers and knowledge related to traveler’s medicine. The goal of pre-travel consultation is to improve the understanding of travelers about travel-related health hazards and diseases.

The number of international travelers has been increasing at a steady pace, and travel-related health issues are rising frequently

Development of New Treatments

Antibiotics is a widely prescribed treatment for traveler’s diarrhea. Antibiotics such as ciprofloxacin, quinolones azithromycin, and rifaximin are prescribed for the treatment of traveler’s diarrhea.

However, overuse of antibiotics leads to antibiotic resistance. Thus, new antibiotics are being introduced to overcome microbial resistance by antibiotics and make the traveler’s diarrhea treatment effective

Increase in prevalence of infectious diseases, such as diarrhea and traveler’s diarrhea, is fueling the demand for new development of treatment. Consequently, numerous clinical trials are conducted in order to develop safe and effective treatment. For instance, clinical trial was conducted in Bangladesh for inactivated vaccine candidate against enterotoxigenic E. coli, and it was found to be safe in children and adults for the treatment of diarrhea.

Industry players are focused on research and development to introduce new therapeutic products for the treatment of traveler’s diarrhea

Thus, the new development of treatment for traveler’s diarrhea is likely fuel the global market

Trend of Self-medication Using OTC Products and Misuse of Antibiotics Hamper Traveler’s Diarrhea Treatment Market

Increase in use of over the counter medication for the treatment of traveler’s diarrhea is anticipated to hamper the market. For instance, according to an article published in The Journal of Life and Environmental Sciences, the study conducted during 2013-2014 in China Mainland, the estimated rate of antibiotic misuse was 35.12%

Rise in use of antibiotics increases the risk of antibiotic resistance. Therefore, as per WHO guidelines, the use of antibiotics is restricted to cholera with severe dehydration and bloody diarrhea.

Traveler’s Diarrhea Treatment Market: Competition Landscape

This report profiles major players in the global traveler’s diarrhea treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments

The global traveler’s diarrhea treatment market is moderately fragmented, with presence of a few large-scale players in international markets and several small-scale players in regional markets. Top 4 to 5 players hold a major share of the global traveler’s diarrhea treatment market.

Prominent players operating in the global traveler’s diarrhea treatment market include -

• Johnson & Johnson (Johnson & Johnson Consumer Inc.)
• Bausch Health Companies Inc. (Salix Pharmaceuticals)
• COSMO PHARMACEUTICALS
• Immuron
• Valneva SE
• Sun Pharmaceutical Industries Ltd.
• Norgine
• Perrigo Company plc
• Bayer AG

Key Questions Answered in the Traveler’s Diarrhea Treatment Market Report

• What is the scope of growth of product companies in the traveler’s diarrhea treatment market?
• What will be the Y-o-Y growth of the traveler’s diarrhea treatment market between 2019 and 2027?
• What is the influence of changing trends in technologies on the global traveler’s diarrhea treatment market?
• Will North America continue to be the most profitable regional market for traveler’s diarrhea treatment product providers?
• Which factors will impede the growth of the traveler’s diarrhea treatment market during the forecast period?
• Which are the leading companies in the global traveler’s diarrhea treatment market?

Traveler’s Diarrhea Treatment Market - Segmentation

Drug Class

• Oral Rehydration Therapy (ORS)
• Antidiarrheal Agents
• Antibiotics
• Azithromycin
• Ciprofloxacin
• Quinolones
• Rifaximi
• Vaccines/Prophylactics
• Others

Pathogen

• Bacteria
• E. Coli
• Salmonella Spp
• Others
• Viruses
• Protozoa
• Giardiasis
• Cryptosporidium parvum

Age Group

• Adults
• Children

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Traveler’s Diarrhea Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

            4.3.1.1. Surge in Number of Travelers

            4.3.1.2. Awareness Among Travelers 

            4.3.1.3. Evolution of Pathogens and Antimicrobial Resistance

            4.3.1.4. Rise in Number of Food Contamination Cases

            4.3.1.5. New Therapeutics in Development

        4.3.2. Restraints

            4.3.2.1. Trend of Self-medication Using OTC Products and Misuse of Antibiotics

            4.3.2.2. Awareness about Hygiene 

            4.3.2.3. Introduction of Generic Products

        4.3.3. Opportunities

    4.4. Global Traveler’s Diarrhea Treatment Market Analysis and Forecasts, 2017–2030

5. Market Outlook

    5.1. Overview of Guidelines for Diagnosis & Treatment of Traveler’s Diarrhea 

    5.2. Private/Public Sector Drug Supply Chain by Region/Country

    5.3. Pipeline Analysis

    5.4. Epidemiology of Traveler’s Diarrhea by Region/Sub-region

    5.5. Overview of Causes/Percentage of Bacteria, Viruses and Protozoa Causing Traveler’s Diarrhea 

6. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Drug Class  

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class, 2017–2030

        6.3.1. Oral Rehydration Therapy (ORS)

        6.3.2. Antidiarrheal Agents

            6.3.2.1. Antibiotics

            6.3.2.2. Azithromycin

            6.3.2.3. Ciprofloxacin

            6.3.2.4. Quinolones

            6.3.2.5. Rifaximin

        6.3.3. Vaccines/prophylactics

        6.3.4. Others

    6.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Drug Class  

7. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Pathogen

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2030

        7.3.1. Bacteria

            7.3.1.1. E. Coli

            7.3.1.2. Salmonella Spp

            7.3.1.3. Others

        7.3.2. Viruses

        7.3.3. Protozoa 

            7.3.3.1. Giardiasis

            7.3.3.2. Cryptosporidium parvum

    7.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Pathogen

8. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Age 

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2030

        8.3.1. Adults 

        8.3.2. Children

    8.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Age 

9. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Distribution Channel 

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2030

        9.3.1. Retail Pharmacies

        9.3.2. Hospital Pharmacies

        9.3.3. Online Pharmacies

    9.4. Global Traveler’s Diarrhea Treatment Market Attractiveness, by Distribution Channel 

10. Global Traveler’s Diarrhea Treatment Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Traveler’s Diarrhea Treatment Market Value Forecast, by Region

        10.2.1. North America 

        10.2.2. Europe 

        10.2.3. Asia Pacific 

        10.2.4. Latin America 

        10.2.5. Middle East & Africa 

    10.3.  Global Traveler’s Diarrhea Treatment Market Attractiveness, by Region

11. North America Traveler’s Diarrhea Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2030

        11.2.1. Oral Rehydration Therapy (ORS)

        11.2.2. Antidiarrheal Agents

        11.2.3. Antibiotics

            11.2.3.1. Azithromycin

            11.2.3.2. Ciprofloxacin

            11.2.3.3. Quinolones

            11.2.3.4. Rifaximin

        11.2.4. Vaccines/prophylactics

        11.2.5. Others

    11.3. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2030

        11.3.1. Bacteria

            11.3.1.1. E. Coli

            11.3.1.2. Salmonella Spp

            11.3.1.3. Others

        11.3.2. Viruses

        11.3.3. Protozoa 

            11.3.3.1. Giardiasis

            11.3.3.2. Cryptosporidium parvum

    11.4. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2030

        11.4.1. Adults 

        11.4.2. Children

    11.5. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2030

        11.5.1. Retail Pharmacies

        11.5.2. Hospital Pharmacies

        11.5.3. Online Pharmacies

    11.6. North America Traveler’s Diarrhea Treatment Market Value Forecast, by Country, 2017–2030

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Traveler’s Diarrhea Treatment Market Attractiveness Analysis 

        11.7.1. By Drug Class  

        11.7.2. By Pathogen

        11.7.3. By Age 

        11.7.4. By Distribution Channel 

        11.7.5. By Country

12. Europe Traveler’s Diarrhea Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2030

        12.2.1. Oral Rehydration Therapy (ORS)

        12.2.2. Antidiarrheal Agents

        12.2.3. Antibiotics

            12.2.3.1. Azithromycin

            12.2.3.2. Ciprofloxacin

            12.2.3.3. Quinolones

            12.2.3.4. Rifaximin

        12.2.4. Vaccines/prophylactics

        12.2.5. Others

    12.3. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2030

        12.3.1. Bacteria

            12.3.1.1. E. Coli

            12.3.1.2. Salmonella Spp

            12.3.1.3. Others

        12.3.2. Viruses

        12.3.3. Protozoa 

            12.3.3.1. Giardiasis

            12.3.3.2. Cryptosporidium parvum

    12.4. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2030

        12.4.1. Adults 

        12.4.2. Children

    12.5. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2030

        12.5.1. Retail Pharmacies

        12.5.2. Hospital Pharmacies

        12.5.3. Online Pharmacies

    12.6. Europe Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2030

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Traveler’s Diarrhea Treatment Market Attractiveness Analysis 

        12.7.1. By Drug Class  

        12.7.2. By Pathogen

        12.7.3. By Age 

        12.7.4. By Distribution Channel 

        12.7.5. By Country/Sub-region

13. Asia Pacific Traveler’s Diarrhea Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class, 2017–2030

        13.2.1. Oral Rehydration Therapy (ORS)

        13.2.2. Antidiarrheal Agents

        13.2.3. Antibiotics

            13.2.3.1. Azithromycin

            13.2.3.2. Ciprofloxacin

            13.2.3.3. Quinolones

            13.2.3.4. Rifaximin

        13.2.4. Vaccines/prophylactics

        13.2.5. Others

    13.3. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2030

        13.3.1. Bacteria

            13.3.1.1. E. Coli

            13.3.1.2. Salmonella Spp

            13.3.1.3. Others

        13.3.2. Viruses

        13.3.3. Protozoa 

            13.3.3.1. Giardiasis

            13.3.3.2. Cryptosporidium parvum

    13.4. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2030

        13.4.1. Adults 

        13.4.2. Children

    13.5. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2030

        13.5.1. Retail Pharmacies

        13.5.2. Hospital Pharmacies

        13.5.3. Online Pharmacies

    13.6. Asia Pacific Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2030

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Traveler’s Diarrhea Treatment Market Attractiveness Analysis 

        13.7.1. By Drug Class  

        13.7.2. By Pathogen

        13.7.3. By Age 

        13.7.4. By Distribution Channel 

        13.7.5. By Country/Sub-region

14. Latin America Traveler’s Diarrhea Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Latin America Traveler’s Diarrhea Market Value Forecast, by Drug Class , 2017–2030

        14.2.1. Oral Rehydration Therapy (ORS)

        14.2.2. Antidiarrheal Agents

        14.2.3. Antibiotics

            14.2.3.1. Azithromycin

            14.2.3.2. Ciprofloxacin

            14.2.3.3. Quinolones

            14.2.3.4. Rifaximin

        14.2.4. Vaccines/prophylactics

        14.2.5. Others

    14.3. Latin America Traveler’s Diarrhea Market Value Forecast, by Pathogen, 2017–2030

        14.3.1. Bacteria

            14.3.1.1. E. Coli

            14.3.1.2. Salmonella Spp

            14.3.1.3. Others

        14.3.2. Viruses

        14.3.3. Protozoa 

            14.3.3.1. Giardiasis

            14.3.3.2. Cryptosporidium parvum

    14.4. Latin America Traveler’s Diarrhea Market Value Forecast, by Age, 2017–2030

        14.4.1. Adults 

        14.4.2. Children

    14.5. Latin America Traveler’s Diarrhea Market Value Forecast, by Distribution Channel, 2017–2030

        14.5.1. Retail Pharmacies

        14.5.2. Hospital Pharmacies

        14.5.3. Online Pharmacies

    14.6. Latin America Traveler’s Diarrhea Market Value Forecast, by Country/Sub-region, 2017–2030

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Traveler’s Diarrhea Market Attractiveness Analysis 

        14.7.1. By Drug Class  

        14.7.2. By Pathogen

        14.7.3. By Age 

        14.7.4. By Distribution Channel 

        14.7.5. By Country/Sub-region

15. Middle East & Africa Traveler’s Diarrhea Treatment Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Drug Class , 2017–2030

        15.2.1. Oral Rehydration Therapy (ORS)

        15.2.2. Antidiarrheal Agents

        15.2.3. Antibiotics

            15.2.3.1. Azithromycin

            15.2.3.2. Ciprofloxacin

            15.2.3.3. Quinolones

            15.2.3.4. Rifaximin

        15.2.4. Vaccines/prophylactics

        15.2.5. Others

    15.3. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Pathogen, 2017–2030

        15.3.1. Bacteria

            15.3.1.1. E. Coli

            15.3.1.2. Salmonella Spp

            15.3.1.3. Others

        15.3.2. Viruses

        15.3.3. Protozoa 

            15.3.3.1. Giardiasis

            15.3.3.2. Cryptosporidium parvum

    15.4. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Age, 2017–2030

        15.4.1. Adults 

        15.4.2. Children

    15.5. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Distribution Channel, 2017–2030

        15.5.1. Retail Pharmacies

        15.5.2. Hospital Pharmacies

        15.5.3. Online Pharmacies

    15.6. Middle East & Africa Traveler’s Diarrhea Treatment Market Value Forecast, by Country/Sub-region, 2017–2030

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa Traveler’s Diarrhea Treatment Market Attractiveness Analysis 

        15.7.1. By Drug Class  

        15.7.2. By Pathogen

        15.7.3. By Age 

        15.7.4. By Distribution Channel 

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix (By Tier and Size of companies)

    16.2. Market Share Analysis/Ranking By Company (2018)

    16.3. Company Profiles

        16.3.1. Johnson & Johnson (Johnson & Johnson Consumer Inc.)

            16.3.1.1. Company Overview

            16.3.1.2. Company Financials

            16.3.1.3. Growth Strategies

            16.3.1.4. SWOT Analysis

        16.3.2. Bausch Health Companies Inc. (Salix Pharmaceuticals)

            16.3.2.1. Company Overview

            16.3.2.2. Company Financials

            16.3.2.3. Growth Strategies

            16.3.2.4. SWOT Analysis

        16.3.3. COSMO PHARMACEUTICALS

            16.3.3.1. Company Overview

            16.3.3.2. Company Financials

            16.3.3.3. Growth Strategies

            16.3.3.4. SWOT Analysis 

        16.3.4. Immuron

            16.3.4.1. Company Overview

            16.3.4.2. Company Financials

            16.3.4.3. Growth Strategies

            16.3.4.4. SWOT Analysis

        16.3.5. Valneva SE

            16.3.5.1. Company Overview

            16.3.5.2. Company Financials

            16.3.5.3. Growth Strategies

            16.3.5.4. SWOT Analysis

        16.3.6. Sun Pharmaceutical Industries Ltd.

            16.3.6.1. Company Overview

            16.3.6.2. Company Financials

            16.3.6.3. Growth Strategies

            16.3.6.4. SWOT Analysis

        16.3.7. Norgine

            16.3.7.1. Company Overview

            16.3.7.2. Company Financials

            16.3.7.3. Growth Strategies

            16.3.7.4. SWOT Analysis

        16.3.8. Perrigo Company plc

            16.3.8.1. Company Overview

            16.3.8.2. Company Financials

            16.3.8.3. Growth Strategies

            16.3.8.4. SWOT Analysis

        16.3.9. Bayer AG

            16.3.9.1. Company Overview

            16.3.9.2. Company Financials

            16.3.9.3. SWOT Analysis